Qiagen N.V. (QGEN) Q4 2019 Earnings Call Transcript

Qiagen N.V. (QGEN) Q4 2019 Earnings Call Transcript

[Operator instructions] At this time, I would like to introduce your host, John Gilardi, vice president of corporate communications and investor relations at QIAGEN.. The speakers today are Thierry Bernard, the interim CEO of QIAGEN and also senior vice president of our molecular diagnostics business; and Roland Sackers, chief financial officer.. As we go through this period of change at QIAGEN, we delivered on our commitments to you all, and we continue to focus on attractive growth opportunities across the continuum from life science to molecular diagnostic.. As we said also in our Q3 earnings call, we are realistic about our challenges that began in mid-2019, especially in the Asian markets, particularly China, as well as the decline in revenues from companion diagnostic co-development due to the changes in our clinical NGS strategy announced in October.. My second key message for today is that we delivered on the sales outlook for the full-year 2019 and also exceeded the target we had set for adjusted EPS.. Net sales '19 were $1.53 billion, raising 4% at CER against our target for growth at the same rate.. The drop in companion diagnostic co-development revenues related to our strategic decision in NGS cost us